Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

© 2015 Elsevier B.V. This review of the publications between July 2013 and December 2014 on antihelminthic drugs includes albendazole, ivermectin, levamisole, mebendazole, praziquantel, and tribendimidine. Cases of hepatotoxicity in children due to albendazole therapy are reported. The first case of possible hematologic disorder associated with hepatitis resulting from albendazole therapy is reported. Fatal neurotoxicity with ivermectin treatment is presented. The frequency of adverse drug reactions with ivermectin in the treatment of onchocerciasis is compared with moxidectin. Levamisole-induced leukoencephalopathy in a patient on therapy for ascariasis is described. Levamisole is a common adulterant of street cocaine and can cause a wide range of adverse reactions including neutropenia, agranulocytosis, vasculitis and/or vasculopathy, with a particular predilection for the ears, causing necrosis of the pinnae, skin necrosis, purpuric eruptions, antiphospholipid antibody syndrome, and microvascular thrombosis. A case of suspected pyoderma gangrenosum from intake of cocaine contaminated with levamisole is reported. Adverse reactions from levamisole-contaminated cocaine affecting renal and cardiovascular systems have also been reported, and these are included in the special review section. Results of systematic reviews evaluating the safety of praziquantel are reported. The relationship between therapy with praziquantel for treatment of liver fluke and the risk of cholangiocarcinoma is systematically reviewed. The safety of tribendimidine compared with praziquantel in the treatment of helminthic infections is evaluated..

Original publication




Journal article

Publication Date





367 - 381